Dova Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported loss from operations was $13,677,000 against $5,231,000 a year ago. Net loss was $13,770,000 against $5,424,000 a year ago. Basic and diluted loss per share was $0.52 against $0.31 a year ago. R&D expenses were $3.4 million in the first quarter of 2018 compared with $4.3 million for the first quarter of 2017. The decrease is largely attributable to the completion of the ADAPT-1 and ADAPT-2 clinical trials in January 2017, partially offset by the initiation of the presurgery thrombocytopenia or PST study.

The company expect net losses to continue to increase in 2018, due to the increases in R&D and G&A expenses. However, The company anticipates that net loss will be partially offset by new potential revenue stream, generated from the potential launch of avatrombopag in June 2018.